DIRS.INFO The most relevant business & tech news

☆ Sanofi CEO under pressure to woo investors after spending shock
▼ + stars: | 2023-12-05 | by ( Ludwig Burger | ) www.reuters.com time to read: +5 min

[1/2] Paul Hudson, chief executive officer of Sanofi, speaks during the annual results news conference at the company's headquarters in Paris, France, February 4, 2022. The market's shock reaction, compounded by a lack of details of the spending push, overshadowed Sanofi's plan to list its consumer unit, in line with an industry trend. David Song, a portfolio manager and investment partner at Tema ETF, said: "The narrative of Sanofi has been a margin expansion, earnings-driven story for a lot of investors." "Shouldn't investors give credit to managements who care about long-term shareholder value creation?," said Song. ($1 = 0.9206 euros)Reporting by Ludwig Burger; Editing by Josephine Mason and Emelia Sithole-MatariseOur Standards: The Thomson Reuters Trust Principles.

Persons: Paul Hudson, Sanofi, Benoit Tessier, Hudson, Dan Lyons, Janus Henderson, Markus Manns, David Song, Fabian Wenner, Julius Baer, Union's Manns, Janus Henderson's Lyons, Johnson, Song, Ludwig Burger, Josephine Mason, Emelia Organizations: REUTERS, Reuters, Janus Henderson Investors, Germany's Union Investment, Tema, Thomson Locations: Paris, France, British, Hudson, Denver, Swiss, Tema

Foundation models like the one built by Microsoft (MSFT.O)-backed OpenAI are AI systems trained on large sets of data, with the ability to learn from new data to perform various tasks. In a meeting of the countries' economy ministers on Oct. 30 in Rome, France persuaded Italy and Germany to support a proposal, sources told Reuters. Until then, negotiations had gone smoothly, with lawmakers making compromises across several other conflict areas such as regulating high-risk AI, sources said. France-based AI company Mistral and Germany's Aleph Alpha have criticised the tiered approach to regulating foundation models, winning support from their respective countries. Other pending issues in the talks include definition of AI, fundamental rights impact assessment, law enforcement exceptions and national security exceptions, sources told Reuters.

Persons: Carlos Barria, Thierry Breton, Geoffrey Hinton, Alpha, Mistral, Mark Brakel, Supantha Mukherjee, Josephine Mason, Alexander Smith Organizations: Technology, Intelligence, REUTERS, Rights, Reuters, Foundation, Microsoft, European Commission, Mistral, Lawmakers, Life Institute, Thomson Locations: San Francisco, California, U.S, Rights STOCKHOLM, BRUSSELS, LONDON, France, Germany, Italy, Rome, Spain, Belgium, Stockholm

☆ GSK CEO says RSV vaccine revenue to top 1 bln pounds in first year
▼ + stars: | 2023-11-30 | by ( Michele Gershberg | ) www.reuters.com time to read: +4 min

GSK had previously forecast 2023 sales for Arexvy between 900 million pounds and 1 billion pounds ($1.26 billion) following a strong U.S. launch. "We’re delighted with the start of our RSV vaccine," Walmsley said in a Reuters Newsmaker interview. The U.S. Food and Drug Administration (FDA) approved Arexvy for adults aged 60 years or older in May and GSK launched the vaccine in the U.S. later in the year. GSK made close to two-thirds of RSV doses given in the United States since early September, according to IQVIA data earlier this month. On Tuesday, rival Pfizer (PFE.N) said it was disappointed in the performance of its RSV shot Abrysvo compared with GSK.

Persons: Walmsley, GSK's, Emma Walmsley, We’re, David Denton, AstraZeneca's, commercialise Johnson, Ludwig Burger, Michael Erman, Josephine Mason, Kirsten Donovan, Elaine Hardcastle Organizations: GSK, Reuters, U.S . Food, Drug Administration, Pfizer, U.S, Thomson Locations: British, U.S, Europe, Japan, United States

☆ Novo Nordisk finds compounded Wegovy up to 33% impure, sues Florida pharmacies
▼ + stars: | 2023-11-30 | by ( Patrick Wingrove | ) www.reuters.com time to read: +3 min

[1/2] Injection pens of Novo Nordisk's weight-loss drug Wegovy are shown in this photo illustration in Oslo, Norway, November 21, 2023. The Danish drugmaker said it found impurities in all the drugs tested from Wells Pharmacy and Brooksville Pharmaceuticals, both based in Florida. Novo said the compounded versions of Wegovy tested from Brooksville were also less potent than advertised, with one sample shown to be at least 19% weaker than indicated. The drugmaker has already filed 12 lawsuits against medical spas, weight-loss clinics and compounding pharmacies offering products that claim to contain semaglutide. The case against Wells was filed in the U.S. District Court, Middle District of Florida, Ocala division and the suit against Brooksville in U.S. District Court, Middle District of Florida, Tampa division.

Persons: Victoria Klesty, Danish drugmaker, Novo, Brooksville, ” Jason Brett, Eli Lilly, Mounjaro, Wells, Patrick Wingrove, Josephine Mason, Bill Berkrot, Jane Merriman Organizations: REUTERS, Novo Nordisk, Wells Pharmacy, Brooksville Pharmaceuticals, U.S . Food, Drug Administration, FDA, Novo's, Middle District of, Brooksville, Thomson Locations: Oslo, Norway, Victoria, Danish, Florida, Wells, U.S, Middle District, Middle District of Florida, Ocala, Tampa

☆ OpenAI's interim CEO pledges probe into Altman's exit, reform management
▼ + stars: | 2023-11-20 | by ( ) www.reuters.com time to read: +2 min

[1/2] Twitch CEO Emmett Shear speaks in a still image taken from a video interview with Reuters in San Francisco, U.S. which was broadcast in May 2018. Ex-Twitch boss Emmett Shear has been appointed to lead the company behind ChatGPT, replacing Altman following his shock sacking on Friday. Earlier on Monday, OpenAI backer Microsoft (MSFT.O) said Altman will join the company to lead a new advanced artificial intelligence research team. OpenAI Chief Operating Officer Brad Lightcap told staff on Saturday it was over a "breakdown of communications" not "malfeasance". I'm not crazy enough to take this job without board support for commercializing our awesome models," he said.

Persons: Emmett Shear, Sam Altman, Altman, Emmett, Brad Lightcap, I'm, Josephine Mason, Emelia Sithole Organizations: Reuters, REUTERS, Microsoft, Thomson Locations: San Francisco , U.S, U.S, OpenAI

☆ How well-off Brits still buy Ozempic online for weight loss
▼ + stars: | 2023-11-18 | by ( Maggie Fick | ) www.reuters.com time to read: +12 min

NHS diabetes patients – including Gradwell, who went for weeks without full medication – pay nothing for their medication. The shortage persists even after Ozempic's manufacturer Novo Nordisk (NOVOb.CO) launched Wegovy, a semaglutide drug solely for weight loss, in September. Rightangled told Reuters it is within its rights to continue to prescribe Ozempic for weight loss. Two had stopped offering it for weight loss by October, but Rightangled continued to make it available as of Nov. 17, Reuters found. He said his oncologist said that while he could not prescribe Ozempic, it would be good for his health if he took it for weight loss.

Persons: Kim Gradwell, –, John, it's, Rightangled, Gradwell, Penny Ward, I've, Abdullah Sabyah, Ward, Juniper, Ben, Doctors, Novo, Ozempic, semaglutide, prescribers, Rightangled's Sabyah, Tyne wasn't, Gradwell's, Yaasir Mamoojee, We've, Maggie Fick, Marine Strauss, Charlotte Van Campenhout, Chad Terhune, Sara Ledwith, Josephine Mason Organizations: Diabetes, National Health Service, Novo Nordisk, King's College, Department of Health, Social Care, John, Reuters, Oxford University ., NHS, Alliance Healthcare, Alliance, Diabetes UK, NICE, semaglutide, Oxford University, General Pharmaceutical Council, Tyne, Thomson Locations: Dudley , North Tyneside, Britain, Novo, United States, London, U.S, England, Europe, Ozempic, Newcastle, Brussels, Los Angeles

☆ Explainer: What’s behind the scramble for semaglutide?
▼ + stars: | 2023-11-18 | by ( Maggie Fick | ) www.reuters.com time to read: +3 min

Semaglutide, developed by Novo Nordisk (NOVOb.CO) over decades, is the active ingredient in type 2 diabetes treatments Ozempic and Rybelsus, as well as Wegovy, which is used for weight loss only. Semaglutide in injected form was first approved for use in the U.S. as a treatment for type 2 diabetes in 2017. Booming demand for both drugs has propelled Novo Nordisk to its highest-ever profits. People taking part in clinical trials for drugs based on semaglutide may also continue to take it. The curbs will be in force until August 2024, but may end sooner if supplies improve, a spokesperson for the health ministry said.

Persons: Maggie Fick, Marine Strauss, Charlotte Van Campenhout, Josephine Mason, Sara Ledwith Organizations: Novo Nordisk, World Health Organization, International Diabetes Foundation, Supply, BMI, Thomson Locations: Britain, Germany, Belgium, United States, U.S, Denmark, Brussels

☆ How Novo Nordisk makes its weight-loss drug Wegovy
▼ + stars: | 2023-11-01 | by ( Maggie Fick | ) www.reuters.com time to read: +3 min

[1/2] A 0.25 mg injection pen of Novo Nordisk's weight-loss drug Wegovy is shown in this photo illustration in Oslo, Norway, August31, 2023. REUTERS/Victoria Klesty/Illustration/File Photo Acquire Licensing RightsLONDON, Nov 1 (Reuters) - Novo Nordisk (NOVOb.CO) is spending billions of dollars to boost output and ease shortages of its hugely popular, highly effective weight-loss medicine Wegovy. FILL-FINISHNovo has hired Catalent (CTLT.N), a large U.S. contract drug manufacturer, to fill injection pens for Wegovy at two of that company's plants: in Brussels and in Bloomington, Indiana. Novo has also hired another U.S. firm, Thermo Fisher (TMO.N), as a Wegovy pen filler. COMPONENTSThe Wegovy injection pens for the U.S. market slightly differ from those sold in the European markets including Norway, Denmark, Germany and UK, where it has so far launched.

Persons: Victoria Klesty, Catalent, Novo, Wegovy, Maggie Fick, Josephine Mason, Tomasz Janowski Organizations: REUTERS, Novo Nordisk, U.S, Novo, Reuters, PCI Pharma Services, autoinjectors, West Pharmaceutical Services, Stevenato, SCHOTT Pharma, Thomson Locations: Oslo, Norway, August31, Victoria, Danish, Novo, Denmark, U.S, Brussels, Bloomington , Indiana, Greenville , North Carolina, Greenville, Germany, Europe, Swiss

☆ UK AI Safety Summit: who will attend and what’s on the agenda?
▼ + stars: | 2023-10-31 | by ( Martin Coulter | ) www.reuters.com time to read: +4 min

LONDON, Oct 31 (Reuters) - Britain will host the world's first global artificial intelligence (AI) safety summit this week to examine the risks of the fast-growing technology and kickstart an international dialogue on regulation of it. The aim of the summit is to start a global conversation on the future regulation of AI. Currently there are no broad-based global regulations focusing on AI safety, although some governments have started drawing up their own rules. A recent Financial Times report said Sunak plans to launch a global advisory board for AI regulation, modeled on the Intergovernmental Panel on Climate Change (IPCC). When Sunak announced the summit in June, some questioned how well-equipped Britain was to lead a global initiative on AI regulation.

Persons: Olaf Scholz, Justin Trudeau –, Kamala Harris, Ursula von der Leyen, Wu Zhaohui, Antonio Guterres, James, Demis Hassabis, Sam Altman, OpenAI, Elon Musk, “, Stuart Russell, Geoffrey Hinton, Alan Turing, Rishi Sunak, Sunak, Joe Biden, –, Martin Coulter, Josephine Mason, Christina Fincher Organizations: Bletchley, WHO, Canadian, European, United Nations, Google, Microsoft, HK, Billionaire, Alan, Alan Turing Institute, Life, European Union, British, EU, UN, Thomson Locations: Britain, England, Beijing, British, Alibaba, United States, China, U.S

☆ Explainer: Why is Siemens Energy seeking $16 billion state guarantees?
▼ + stars: | 2023-10-29 | by ( ) www.reuters.com time to read: +5 min

The logo of energy technology company Siemens Energy is displayed during the LNG 2023 energy trade show in Vancouver, British Columbia, Canada, July 12, 2023. To make sure it can get the guarantees to fulfil its order backlog, Siemens Energy has turned to the government. Siemens owns a 25.1% stake in Siemens Energy and has not ruled out helping. Siemens still provides around 7 billion euros of performance guarantees to projects Siemens Energy is working on, significantly down from the 40 billion euros at the time of the spin-off around three years ago. Apart from seeking guarantees from the government, banks and Siemens, Siemens Energy said it is "evaluating various measures to strengthen the balance sheet", without elaborating further.

Persons: Chris Helgren, Banks, Roland Busch, hade, Andreas Rinke, Christoph Steitz, Victoria Farr, Andres Gonzalez, Pablo Mayo, Alexander Huebner, Tom Kaeckenhoff, Josephine Mason, Susan Fenton Organizations: Siemens Energy, REUTERS, Siemens, International Chamber of Commerce, German Economy Ministry, SIEMENS, Triton, Pablo Mayo Cerqueiro, Thomson Locations: Vancouver , British Columbia, Canada, downpayments, Berlin, Frankfurt, London, Munich

A 0.25 mg injection pen of Novo Nordisk's weight-loss drug Wegovy is shown in this photo illustration in Oslo, Norway, September 1, 2023. "Supply of Wegovy is the most important thing for specialist healthcare investors covering Novo right now," said Barclays analyst Emily Field. Some analysts said a firm date would ease concerns that Novo's supply constraints could allow rival Eli Lilly (LLY.N) to get ahead, when it launches its Mounjaro weight-loss drug. Eli Lilly, the world's most valuable drug company ahead of Novo, has said it expects U.S. approval for the drug, currently licensed for diabetes, to be used for weight loss by the end of the year. Novo is spending billions to increase Wegovy output and hiring more contract manufacturers to fill the pens.

Persons: Victoria Klesty, Wegovy, Novo, Emily Field, Eli Lilly, Markus Manns, Manns, Catalent, Jefferies, Jacob Gronholt, Pedersen, Maggie Fick, Josephine Mason, Jane Merriman Organizations: REUTERS, Novo Nordisk, Wegovy, Barclays, U.S . Food, Drug Administration, Union Investment, Thomson Locations: Oslo, Norway, Victoria, COPENHAGEN, United States, Danish, Germany, Novo, U.S, Brussels, London

Intra-European travel has been doing very well," said aviation analyst James Halstead, adding that limited planes meant ticket prices could stay high. Britain's easyJet (EZJ.L) said earlier this month it wanted to more than double profits and expand its fleet, even though fuel prices could mean higher ticket prices. Spot Northwest European jet fuel prices were at $957 per metric ton on Wednesday, up 5% from before the assault. JET FUELSome airlines have already warned that rising fuel costs will drive up ticket prices or dampen future earnings. He said ticket prices could go up by a mid-single digit percentage ahead of Christmas.

Persons: Charles de, Benoit Tessier, James Halstead, You've, Michael O'Leary, it's, Neil Glynn, Alexander Irving, Bernstein, Agata Rybska, Natalie Grover, Josephine Mason, Mark Potter Organizations: Lufthansa Airbus, Charles de Gaulle International Airport, REUTERS, Air France, KLM, Lufthansa, Air, Brent, JET, Ryanair, Air Control, Thomson Locations: Charles de Gaulle, Roissy, Paris, Israel, Palestinian, Europe, Air France, Ukraine, Gdansk, London

After two years of negotiations, the bill was approved by the European parliament in May. At Tuesday's meeting which lasted until midnight, lawmakers agreed on most parts of Article 6 of the draft AI Act, one of the stumbling blocks in talks, the sources said, declining to give further details on what was agreed. Article 6 outlines the types of AI systems that will be designated "high risk", and therefore subject to greater regulatory scrutiny, the sources said. Ahead of Tuesday's meeting, Reuters reported citing sources that European lawmakers were yet to agree on several issues leaving any deal off the table until December. Failure to reach a deal could push negotiations to early next year, increasing the risk that discussions are further derailed by European parliament elections in June.

Persons: Dragos Tudorache, Brando Benifei, Benifei, Supantha Mukherjee, Martin Coulter, Elvira Pollina, Josephine Mason, Kirsten Donovan Organizations: Union, Reuters, EU, Thomson Locations: STOCKHOLM, LONDON, MILAN, Stockholm, London, Milan

☆ Exclusive: Lilly hires CordenPharma to make diabetes drug Mounjaro's active ingredient -source
▼ + stars: | 2023-10-19 | by ( Maggie Fick | ) www.reuters.com time to read: +3 min

An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. REUTERS/Mike Segar/File Photo Acquire Licensing RightsLONDON, Oct 19 (Reuters) - Eli Lilly (LLY.N) has hired Switzerland-based contract drugmaker CordenPharma to produce the active ingredient in its diabetes drug Mounjaro, a source familiar with the matter told Reuters on Thursday. Lilly has said it expects U.S. approval for Mounjaro for weight loss by the end of the year. The source told Reuters that CordenPharma's factory in Colorado is under contract to make tirzepatide, the active ingredient in the weekly injection. Analysts estimate the obesity market could be worth as much as $100 billion in the next decade.

Persons: Eli Lilly, Mike Segar, drugmaker, CordenPharma, Lilly, Corden, Maggie Fick, Josephine Mason, Bill Berkrot Organizations: Company, REUTERS, Reuters, CordenPharma, Novo Nordisk, Mounjaro, Thomson Locations: Branchburg , New Jersey, Switzerland, United States, Colorado, Basel, Europe, Boulder , Colorado, Boulder

☆ Web Summit CEO apologises for comments on Israeli conflict
▼ + stars: | 2023-10-17 | by ( ) www.reuters.com time to read: +2 min

JERUSALEM, Oct 17 (Reuters) - Web Summit Chief Executive and founder Paddy Cosgrave on Tuesday apologised for comments he made on the Israeli-Hamas conflict that prompted some technology companies and investors to withdraw plans to attend its conference in Portugal next month. Web Summit, one of the world's largest tech conferences, will take place in Lisbon from Nov. 13-16, with attendees from companies such as Meta (META.O) and Microsoft (MSFT.O) to investors such as Atomico. "War crimes are war crimes even when committed by allies, and should be called out for what they are," wrote Cosgrave, who was born in Ireland. Among executives to have cancelled their participation at Web Summit are AI21 Labs' Ori Goshen; Tome's Keith Peiris; Sequoia Capital partner Ravi Gupta; Yinon Costica, co-founder of Israeli cybersecurity unicorn Wiz; and Y Combinator’s Garry Tan, according to LinkedIn and X posts. Philippe Botteri, CEO of tech investor Accel, said in a LinkedIn post on Monday he would no longer speak at Web Summit.

Persons: Paddy Cosgrave, Cosgrave, I’m, Leo Varadkar's, Israel, Cosgrove, Goshen, Tome's Keith Peiris, Ravi Gupta, Yinon Costica, Y, Garry Tan, Philippe Botteri, Portugal Dor Shapira, Steven Scheer, Supantha Mukherjee, Josephine Mason, Alison Williams, Mark Potter Organizations: Web, Microsoft, Palestinian, Hamas, Irish, AI21 Labs, Sequoia Capital, Thomson Locations: Portugal, Lisbon, Gaza, Israel, Ireland, Jerusalem, Stockholm, London

[1/4] People walk into Jerusalem's Old City via Jaffa Gate, as the conflict wreaks havoc across the tourism sector October 11, 2023. Now they are empty after a devastating attack by Palestinian militant group Hamas in Israel on Oct. 7. InterContinental Hotels (IHG.L) said two of its hotels, Six Senses Shaharut and Hotel Indigo Tel Aviv – Diamond District, were temporarily shut. Australian tour operator Intrepid Travel has called off tours to Israel and Palestinian territories until the end of the year. Odysseys Unlimited has suspended its Israel trips until March 31.

Persons: Sinan Abu Mayzer, Abu Dawoud, Khader Hussein, Jesus, That's, Elias al, Dan Hotels, Isrotel, Dan, Israel, Joanna Plucinska, Steven Scheer, Doyinsola, Yadarisa, Josephine Mason, Mark Potter Organizations: REUTERS, Rights, Palestinian, Hamas, West Bank, Virgin, European, InterContinental Hotels, Indigo, Aviv, Diamond, Israel Central Bureau of Statistics, Arab Hotel Association, Intrepid, Odysseys, NEW, Thomson Locations: City, Jaffa, Rights BETHLEHEM, JERUSALEM, Bethlehem's, Israel, Palestinian, Gaza, Jerusalem, Tel Aviv, United States, European Union, Britain, Europe, Bethlehem, Tel, U.S, West, Australian, Egypt, Jordan, LONDON, Bengaluru

☆ Weight-loss drugs fuel boom for firms that fill syringes
▼ + stars: | 2023-10-09 | by ( Maggie Fick | ) www.reuters.com time to read: +6 min

[1/5] Catalent's automated visual inspection systems that check every pre-filled syringe to ensure product integrity are seen, in Brussels, Belgium, 2023. Eli Lilly's (LLY.N) Mounjaro is expected to be approved for weight-loss in the United States this year. The U.S. Inflation Reduction Act is also boosting development of biologic drugs, some of which are injected. Injectables are increasingly used in elderly care settings, and some new Alzheimer's and generic arthritis drugs are administered by injection. One healthcare investor said CDMOs' ability to boost capacity will determine how fast the obesity drug market grows.

Persons: Wegovy, it's, Savant, Morgan Stanley, Eli Lilly's, Mounjaro, Chris Chen, Cornell Stamoran, Fujifilm Diosynth, Germany's Vetter, Lilly, Marc Casper, CDMOs, Luke Sergott, Catalent, Catalent's Stamoran, Maggie Fick, Patrick Wingrove, Josephine Mason, Catherine Evans Organizations: REUTERS Acquire, Pfizer, HK, Fujifilm, Fujifilm Corp, Novo, Reuters, Research, Insight Partners, Barclays, Thomson Locations: Brussels, Belgium, Handout, United States, WuXi, Europe, GLP, Anagni, Italy, Bloomington , Indiana, U.S, New York

☆ Novo Nordisk's Wegovy bonanza looms large in Denmark
▼ + stars: | 2023-10-05 | by ( Maggie Fick | ) www.reuters.com time to read: +6 min

COPENHAGEN, Oct 5 (Reuters) - The whirlwind success of weight-loss treatment Wegovy is providing a bonanza not just for its developer, Novo Nordisk (NOVOb.CO), but also for its home country of Denmark. Interviews with Danish economists, analysts, and executives at the Novo Nordisk Foundation which controls Novo highlight the benefits to the economy from jobs to private wealth - but also the potential pitfalls of relying on a single, outsized company. Record profits for Novo are projected to generate returns for the Foundation of more than $12 billion in coming years. Novo Nordisk added 3,500 jobs in Denmark in 2022, bringing the total in the country to 21,000 employees, out of 59,000 worldwide, a company spokesperson said. Before Wegovy, "we used to be kind of, 'Isn't Denmark the place where Stockholm is the capital?'"

Persons: Danes, Lars Skovgaard Andersen, Lars Christensen, Wegovy, Mads Krogsgaard Thomsen, " Thomsen, Moller, Thomsen, Melinda Gates, Rasmus Kristian Feldthusen, Maggie Fick, Jacob Gronholt, Alexander Smith, Josephine Mason, Michele Gershberg, Catherine Evans Organizations: Novo Nordisk, Novo Nordisk Foundation, Danske Bank, Copenhagen Business School, Novo, Foundation, Reuters, Novo Holdings, Carlsberg, Maersk, U.S, Melinda Gates Foundation, UK's Wellcome Trust, Wegovy, University of Copenhagen, Nokia, Pedersen, Thomson Locations: COPENHAGEN, Denmark, Stockholm, Copenhagen, Danish, Novo, Europe, North America, Asia, OUTGROWING DENMARK, Finland

☆ Novo Nordisk owner readies for big Wegovy windfall
▼ + stars: | 2023-10-03 | by ( Maggie Fick | ) www.reuters.com time to read: +4 min

COPENHAGEN, Oct 3 (Reuters) - The CEO of Novo Holdings said on Tuesday the controlling shareholder of Danish drugmaker Novo Nordisk (NOVOb.CO) is ready for a huge windfall from the runaway success of weight-loss drug Wegovy. Novo Holdings invests and manages the wealth and assets of the Novo Nordisk Foundation, whose newly bulging coffers could make it a major philanthropist and environmental, social and governance (ESG) investor. He was speaking to a group of journalists in Copenhagen, where the investment company, its owner Novo Nordisk Foundation, and the drugmaker Novo Nordisk are all headquartered. [1/4]Novo Holdings A/S CEO Kasim Kutay speaks at Novo Nordisk Foundation in Hellerup, Denmark, October 3, 2023. Novo Holdings' early-stage investments team now has $200 million to deploy each year, Soren Moller, who heads the seed division, told Reuters.

Persons: Kasim Kutay, Wegovy, Kutay, I've, Morgan Stanley, Ali Withers, Peter Lawaetz Andersen, Andersen, Soren Moller, Maggie Fick, Josephine Mason, Louise Heavens, Catherine Evans Organizations: Novo Holdings, Novo Nordisk, Novo Nordisk Foundation, The Foundation, Holdings, Moelis, REUTERS, Foundation, Norway's Coalition, Reuters, Thomson Locations: COPENHAGEN, Danish, Copenhagen, Novo, United States, Hellerup, Denmark, Shanghai, China, Singapore, Boston, San Francisco

An artificial heart by French manufacturer Carmat is seen during an interview with Reuters in Velizy, near Paris, January 11, 2021. Sources said Carmat, which had 24 million euros cash at mid-year, was looking to raise a total of around 100 million. Airbus said this week it had invested 50 million euros in Carmat but did not address whether it would spend more. It most recently invested 10 million euros in March 2022. Matra Defense paid a dividend of 207 million euros to Airbus in 2022, filings show.

Persons: Christian Hartmann, Jean, Luc Lagardere, Alain Carpentier, Carpentier, Stephane Piat, Emmanuel Macron, Thomas Toepfer, Piat, Samir Devani, Carmat, Tim Hepher, Michal Aleksandrowicz, Laura Lenkiewicz, Stephanie Hamel, Josephine Mason, Elaine Hardcastle Organizations: Reuters, REUTERS, Rights, Airbus, PARIS, Lagardere's Matra Defense, Carmat, Rx Securities, FDA, Zurich University, Matra Defense, Thomson Locations: Velizy, Paris, French, Carmat, United States, Lagardere, Taiwan

A few compounds picked by AI are now in development, but those bets will take years to play out. Reuters interviews with more than a dozen pharmaceutical company executives, drug regulators, public health experts and AI firms show, however, that the technology is playing a sizeable and growing role in human drug trials. The U.S. Food and Drug Administration (FDA) said it had received about 300 applications that incorporate AI or machine learning in drug development from 2016 through 2022. Without AI, Bayer said it would have spent millions more, and taken up to nine months longer to recruit volunteers. Finding real-world patients by mining electronic patient data can be done manually, but using AI speeds up the process dramatically.

Persons: Dado Ruvic, Jeffrey Morgan, Amgen, Badhri Srinivasan, Sameer Pujari, drugmaker Bayer, Bayer, Blythe Adamson, Roche, Richard Pazdur, Gen Li, John Concato, Natalie Grover, Martin Coulter, Julie Steenhuysen, Josephine Mason, David Clarke Organizations: Pharmaceutical Research, REUTERS, Pharmaceutical, Bayer, Novartis, Deloitte, U.S . Food, Drug Administration, Reuters, World Health, Flatiron Health, FDA, European Medicines Agency, FDA's Oncology, Excellence, Medical, FDA's Center, Drug, Research, Thomson Locations: U.S, Johannesburg, Texas, Finland, United States, London, Chicago

☆ Exclusive: U.S. FDA found lapses at Novo's main U.S. factory in May 2022 -report
▼ + stars: | 2023-09-20 | by ( Maggie Fick | ) www.reuters.com time to read: +4 min

Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. A Form 483 is a type of agency report containing "observations" that FDA inspectors "deem to be objectionable". The FDA did not immediately respond to a request for comment on the report, but usually does not comment on inspections. The report from the May 2022 inspection shows that FDA officials found the factory had failed to include one type of bacteria, abbreviated as B. cepacia, on its list of "objectionable organisms". Analysts at Barclays and Jefferies said in notes this week that, although investors may be concerned by news of potential manufacturing issues, they saw minimal impact on Novo's production of semaglutide.

Persons: Andrew Kelly, Clayton, Jefferies, Steven Lynn, Maggie Fick, Josephine Mason, Mark Potter Organizations: Food and Drug Administration, FDA, REUTERS, Novo Nordisk, Reuters, U.S . Food, Drug Administration, Barclays, Manufacturing, Thomson Locations: White Oak , Maryland, U.S, North America, Clayton , North Carolina

☆ Italy plans to ask Apple to upgrade iPhone 12 software in country -govt source
▼ + stars: | 2023-09-15 | by ( ) www.reuters.com time to read: 1 min

A man poses with an Apple iPhone 12 in a mobile phone store in Nantes, France, September 13, 2023. REUTERS/Stephane Mahe Acquire Licensing RightsMILAN, Sept 15 (Reuters) - Italy plans to ask Apple (AAPL.O) to issue a software update for iPhone 12 users in the country, according to a government source, after the U.S. company offered to make similar changes in France to end a row with regulators there over breaches of radiation exposure limits. Reporting by Elvira Pollina in Milan; writing by Josephine Mason; editing by Jason NeelyOur Standards: The Thomson Reuters Trust Principles.

Persons: Stephane Mahe, Elvira Pollina, Josephine Mason, Jason Neely Organizations: Apple, REUTERS, U.S ., Thomson Locations: Nantes, France, Italy, U.S, Milan

☆ German regulator is contact with France on Europe-wide solution over Apple iPhone 12 issue
▼ + stars: | 2023-09-15 | by ( ) www.reuters.com time to read: 1 min

An Apple iPhone 12 is pictured in a mobile phone store in Nantes, France, Sept. 13, 2023. REUTERS/Stephane Mahe/File Photo Acquire Licensing RightsFRANKFURT, Sept 15 (Reuters) - Germany's telecom network regulator said on Friday it was in touch with French authorities about a Europe-wide solution to radiation concerns with Apple's (AAPL.O) iPhone 12 which prompted France to halt sales of the model this week. The comment came after Apple said it would issue a software update for iPhone 12 users in France to settle the matter. The regulator did not give further detail or say if a solution for the bloc would include a software upgrade. Reporting by Hakan Ersen in Frankfurt; writing by Josephine Mason; editing by Jason NeelyOur Standards: The Thomson Reuters Trust Principles.

Persons: Stephane Mahe, Apple, Hakan Ersen, Josephine Mason, Jason Neely Organizations: Apple, REUTERS, Rights, Thomson Locations: Nantes, France, Europe, Frankfurt

FRANKFURT, Sept 14 (Reuters) - Bayer's (BAYGn.DE) new CEO plans to cut management jobs to speed up decision-making as a first step to overhaul the embattled German industrial group, which is facing investor pressure to break up, three people familiar with the matter said. But the new CEO will likely have only a short respite period to come up with concrete strategic proposals. Anderson has been tasked with reviving Bayer's share price, which has underperformed rivals, weighed down by the lingering costs of U.S. weedkiller litigation. Anderson said last month he was not ruling out any options as part of his review of the company's strategy and structure, saying he was "leaving no stone unturned". He added he would provide an initial update in the coming months and detailed plans in early 2024.

Persons: Bill Anderson, Anderson, Roche, Oliver Kohlhaas, Kohlhaas, Werner Baumann, Ludwig Burger, Patricia Weiss, Emma, Victoria Farr, Josephine Mason, David Holmes Organizations: Bayer, McKinsey, Artisan Partners, Reuters, Bluebell Capital Partners, Thomson Locations: FRANKFURT, Frankfurt

Search resuls for: "Josephine Mason"

25 mentions found